Loading…
Japanese biotech developing oncolytic virus therapies and antiviral drugs, notably Telomelysin for cancer.
Japanese biotech developing oncolytic virus therapies and antiviral drugs, notably Telomelysin for cancer.
Depends on raising capital and licensing deals to fund trials. Oncolytic viruses are viruses engineered to infect and destroy cancer cells while sparing healthy tissue; Telomelysin uses a viral control element that switches on only in cells with an active telomerase, an enzyme most cancers use.
In one line: A small-cap Japanese oncolytic-virus biotech, akin to early Replimune.
Moat: narrow (IP / patents). Proprietary oncolytic-virus technology platform, though still largely pre-commercial.
Headquarters: Tokyo, Japan · Founded: 2004 · Employees: 38
Size Oncolys BioPharma (4588.T) is a Japan Health Care company (Biotechnology) with a market value of $1.39B, the 598th largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥7,400 on 6 Nov 2026.
Performance Over six months the shares gained 162.4%, against -21.2% for the median peer and +1.8% for the Japan market (cap-weighted) — highest of 19 in its peer set.
Growth Revenue grew 1,662.4% over the last twelve months (peer median +5.5%); the operating margin is -303.0% (peer median -3.9%).
Valuation It trades at 429.8× enterprise value to sales against a peer median of 7.0× (3rd most expensive of 14).
Capital Return on invested capital runs 133.8 points below its cost of capital (12.2% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥503M | ¥28.5M | ¥31.4M | ¥63.0M | ¥976M |
| Revenue growth | — | -9% | -50% | -94% | — |
| Gross profit | ¥503M | ¥28.3M | ¥30.6M | ¥30.6M | ¥338M |
| EBITDA | -¥1.52B | -¥2.02B | -¥1.68B | -¥1.93B | -¥1.20B |
| Net income | -¥1.51B | -¥2.06B | -¥1.68B | -¥1.94B | -¥1.15B |
| Free cash flow | n/a | -¥1.94B | -¥2.02B | -¥1.34B | -¥1.72B |
| Capital expenditure | n/a | ¥3.01M | ¥3.52M | ¥5.69M | ¥1.36M |
| Total debt | ¥799M | ¥320M | ¥325M | ¥315M | ¥394M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Oncolys BioPharma 4588.T | $1.39B | +162% | +1,662% | -303% | 429.8× | n/a |
| Replimune REPL | $2.05B | +547% | n/a | n/a | n/a | n/a |
| Amgen AMGN | $249B | +40% | +9% | 36% | 7.4× | 1.8% |
| Astellas Pharma 4503.T | $28.2B | +11% | +19% | 23% | 1.9× | -11.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4588.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.3% | -3.0% | 4th highest of 21 |
| 6-month return | +162.4% | -21.2% | highest of 19 |
| Distance from 52-week high | -12.4% | -41.7% | 4th highest of 21 |
| Revenue growth (TTM) | +1,662.4% | +5.5% | highest of 16 |
| Operating margin | -303.0% | -3.9% | 5th lowest of 15 |
| EV / Sales | 429.8× | 7.0× | 3rd most expensive of 14 |
| ROIC minus cost of capital | -133.8 pp | -1.6 pp | 2nd lowest of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Oncolys BioPharma 4588.T | Japan | $1.39B | +162% | +1,662% | -303% | 429.8× | n/a | n/a |
| AnaptysBio ANAB | United States | $1.39B | -33% | +93% | 56% | 6.3× | -1.2% | +25.6% |
| Hualan Biological Vaccine 301207.SZ | China | $1.39B | -21% | -28% | -7% | 10.3× | 36.5% | -13.1% |
| Pacific Shuanglin Bio-pharmacy 000403.SZ | China | $1.38B | -19% | +1% | 10% | 3.8× | n/a | n/a |
| Taysha Gene Therapies TSHA | United States | $1.41B | -36% | -32% | -2,855% | 184.6× | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.41B | +43% | -13% | -359% | 743.5× | n/a | n/a |
| Mineralys Therapeutics MLYS | United States | $1.36B | -48% | n/a | n/a | n/a | n/a | n/a |
| Kardigan KARD | United States | $1.45B | n/a | n/a | n/a | n/a | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.45B | -38% | n/a | n/a | n/a | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.46B | -13% | +1,084% | -81% | 7.2× | n/a | n/a |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.49B | +126% | +5% | -1,720% | 1,640.0× | n/a | n/a |
| Liaoning Chengda Biotechnology 688739.SS | China | $1.28B | -10% | -9% | 0% | 2.5× | 8.8% | -7.0% |
| uniQure QURE | United States | $1.51B | -22% | +30% | -1,093% | 66.8× | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.52B | -26% | +17% | 38% | 4.4× | -7.9% | +15.0% |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.53B | -41% | +25% | 33% | n/a | n/a | n/a |
| Inhibrx Biosciences INBX | United States | $1.24B | -37% | -100% | n/a | n/a | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.55B | -18% | +31% | 13% | 1.8× | -4.1% | +33.5% |
| SpyGlass Pharma SGP | United States | $1.24B | +58% | n/a | n/a | n/a | n/a | n/a |
| Duality Biotherapeutics 9606.HK | Hong Kong | $1.23B | -60% | -5% | -181% | 7.0× | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.57B | n/a | n/a | n/a | n/a | n/a | n/a |
| Akums Drugs and Pharmaceuticals AKUMS.NS | India | $1.22B | +34% | +18% | 10% | 2.1× | 15.8% | +9.9% |